NasdaqGM:APM

Stock Analysis Report

Executive Summary

Aptorum Group Limited, a pharmaceutical company, develops and commercializes a range of therapeutic and diagnostic technologies to treat unmet medical needs.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Share Price & News

How has Aptorum Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.4%

APM

4.6%

US Biotechs

3.4%

US Market


1 Year Return

n/a

APM

-10.1%

US Biotechs

5.4%

US Market

Return vs Industry: Insufficient data to determine how APM performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how APM performed against the US Market.


Shareholder returns

APMIndustryMarket
7 Day0.4%4.6%3.4%
30 Day-5.1%-2.4%-1.0%
90 Day-28.1%-2.1%-0.4%
1 Yearn/a-9.4%-10.1%7.7%5.4%
3 Yearn/a14.9%10.9%46.2%36.8%
5 Yearn/a2.3%-2.7%65.6%47.5%

Price Volatility Vs. Market

How volatile is Aptorum Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aptorum Group undervalued compared to its fair value and its price relative to the market?

18.74x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate APM's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate APM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: APM is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: APM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate APM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: APM is overvalued based on its PB Ratio (18.7x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Aptorum Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-11.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: APM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: APM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: APM's revenue (50.1% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: APM's revenue (50.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: APM is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Aptorum Group performed over the past 5 years?

-163.0%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: APM is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare APM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: APM has a negative Return on Equity (-80.09%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: APM is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: APM is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Aptorum Group's financial position?


Financial Position Analysis

Short Term Liabilities: APM's short term assets ($7.7M) exceeds its short term liabilities ($597.1K)

Long Term Liabilities: APM's short term assets (7.7M) exceeds its long term liabilities (120.9K)


Debt to Equity History and Analysis

Debt Level: APM is debt free.

Reducing Debt: APM had no debt 5 years ago.


Balance Sheet

Inventory Level: APM has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if APM's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: APM has less than a year of cash runway if free cash flow continues to reduce at historical rates of -41.2% each year


Next Steps

Dividend

What is Aptorum Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate APM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate APM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if APM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of APM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Aptorum Group's salary, the management and board of directors tenure and is there insider trading?

1.9yrs

Average management tenure


CEO

Ian Huen (39yo)

2yrs

Tenure

0

Mr. Chung Yuen Huen also known as Ian, is the Founder of Aptorum Group Limited and has been its Chief Executive Officer since October 1, 2017 and serves as its Executive Director. Mr. Huen has been Chairma ...


Management Age and Tenure

1.9yrs

Average Tenure

38.5yo

Average Age

Experienced Management: APM's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Age and Tenure

2.0yrs

Average Tenure

49yo

Average Age

Experienced Board: APM's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Thomas Lee (46yo)

    Head of Research & Development

    • Tenure: 0.5yrs
  • Clark Cheng (39yo)

    Chief Medical Officer & Executive Director

    • Tenure: 0yrs
  • Darren Lui (38yo)

    President & Executive Director

    • Tenure: 0yrs
  • Ian Huen (39yo)

    Founder

    • Tenure: 2yrs
  • Sabrina Khan (38yo)

    Chief Financial Officer

    • Tenure: 2yrs
  • Angel Ng (38yo)

    Chief Operating Officer

    • Tenure: 0.5yrs

Board Members

  • Mirko Scherer (50yo)

    Independent Non-Executive Director

    • Tenure: 2yrs
  • Charles Bathurst (64yo)

    Independent Non-Executive Director

    • Tenure: 2yrs
  • Keith Chan (72yo)

    Member of Scientific Advisory Board

    • Tenure: 0.5yrs
  • Douglas Arner (49yo)

    Independent Non-Executive Director

    • Tenure: 1.5yrs
  • Justin Wu (49yo)

    Independent Non-Executive Director

    • Tenure: 2yrs
  • Clark Cheng (39yo)

    Chief Medical Officer & Executive Director

    • Tenure: 0yrs
  • Darren Lui (38yo)

    President & Executive Director

    • Tenure: 0yrs
  • Ian Huen (39yo)

    Founder

    • Tenure: 2yrs

Company Information

Aptorum Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aptorum Group Limited
  • Ticker: APM
  • Exchange: NasdaqGM
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$467.465m
  • Shares outstanding: 29.04m
  • Website: https://www.aptorumgroup.com

Number of Employees


Location

  • Aptorum Group Limited
  • Guangdong Investment Tower
  • 17th Floor
  • Central
  • Hong Kong

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APMNasdaqGM (Nasdaq Global Market)YesClass A Ordinary SharesUSUSDDec 2018

Biography

Aptorum Group Limited, a pharmaceutical company, develops and commercializes a range of therapeutic and diagnostic technologies to treat unmet medical needs. It focuses on developing various drug molecules ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 00:41
End of Day Share Price2019/10/15 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.